{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:44:18Z","timestamp":1759398258821,"version":"build-2065373602"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,2]]},"DOI":"10.7759\/cureus.93692","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:13:19Z","timestamp":1759396399000},"source":"Crossref","is-referenced-by-count":0,"title":["Neurohumoral Dysregulation in Acute Myocardial Infarction With Chronic Kidney Disease: Implications for Prognosis and Management"],"prefix":"10.7759","author":[{"given":"Oksana","family":"Polianska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Tashchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olha","family":"Hulaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentyna","family":"Olinchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Moskaliuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yevhen","family":"Kushnir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002273","article-title":"Chronic kidney disease management in the United Kingdom: NEOERICA project results","volume":"72","author":"Stevens PE","year":"2007","unstructured":"Stevens PE, O'Donoghue DJ, de Lusignan S, et al.. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007, 72:92-9. 10.1038\/sj.ki.5002273","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.10.047","article-title":"Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study","volume":"57","author":"Tomaschitz A","year":"2011","unstructured":"Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, M\u00e4rz W. Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am J Kidney Dis. 2011, 57:403-14. 10.1053\/j.ajkd.2010.10.047","journal-title":"Am J Kidney Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-158","article-title":"Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): Study protocol for a randomized controlled pilot trial","volume":"15","author":"Ng KP","year":"2014","unstructured":"Ng KP, Jain P, Heer G, et al.. Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): Study protocol for a randomized controlled pilot trial. Trials. 2014, 15:158. 10.1186\/1745-6215-15-158","journal-title":"Trials"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"Parksook WW","year":"2023","unstructured":"Parksook WW, Williams GH. Aldosterone and cardiovascular diseases. Cardiovasc Res. 2023, 119:28-44. 10.1093\/cvr\/cvac027","journal-title":"Cardiovasc Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/157488711795177912","article-title":"Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition","volume":"6","author":"Alfie J","year":"2011","unstructured":"Alfie J, Aparicio LS, Waisman GD. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition. Rev Recent Clin Trials. 2011, 6:134-46. 10.2174\/157488711795177912","journal-title":"Rev Recent Clin Trials"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne RA","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al.. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023, 44:3720-826. 10.1093\/eurheartj\/ehad191","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft DW","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16:31-41. 10.1159\/000180580","journal-title":"Nephron"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105:S117-S314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000078409","article-title":"Adrenal aldosterone biosynthesis is elevated in a model of chronic renal failure--Role of local adrenal renin-angiotensin system","volume":"97","author":"Endemann DH","year":"2004","unstructured":"Endemann DH, Wolf K, Boeger CA, Riegger GA, Kr\u00e4mer BK. Adrenal aldosterone biosynthesis is elevated in a model of chronic renal failure--Role of local adrenal renin-angiotensin system. Nephron Physiol. 2004, 97:p37-44. 10.1159\/000078409","journal-title":"Nephron Physiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03311","article-title":"Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"64","author":"Deo R","year":"2014","unstructured":"Deo R, Yang W, Khan AM, et. al.. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension. 2014, 64:103-10. 10.1161\/HYPERTENSIONAHA.114.03311","journal-title":"Hypertension"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction","volume":"114","author":"Beygui F","year":"2006","unstructured":"Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barth\u00e9l\u00e9my O, Montalescot G. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006, 114:2604-10. 10.1161\/CIRCULATIONAHA.106.634626","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq019","article-title":"Plasma aldosterone levels are associated with increased cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study","volume":"31","author":"Tomaschitz A","year":"2010","unstructured":"Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, M\u00e4rz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010, 31:1237-47. 10.1093\/eurheartj\/ehq019","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefroe.2021.08.001","article-title":"Mineralcorticoid receptor blockers in chronic kidney disease","volume":"41","author":"Erraez S","year":"2021","unstructured":"Erraez S, L\u00f3pez-Mesa M, G\u00f3mez-Fern\u00e1ndez P. Mineralcorticoid receptor blockers in chronic kidney disease. Nefrologia (Engl Ed). 2021, 41:258-75. 10.1016\/j.nefroe.2021.08.001","journal-title":"Nefrologia (Engl Ed)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00421.2002","article-title":"Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1\/2 signaling","volume":"284","author":"Stockand JD","year":"2003","unstructured":"Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1\/2 signaling. Am J Physiol Heart Circ Physiol. 2003, 284:H176-84. 10.1152\/ajpheart.00421.2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-7-3","article-title":"Role of renin-angiotensin-aldosterone system inhibitors in heart failure and chronic kidney disease","volume":"9","author":"Singhania N","year":"2020","unstructured":"Singhania N, Bansal S, Mohandas S, Nimmatoori DP, Ejaz AA, Singhania G. Role of renin-angiotensin-aldosterone system inhibitors in heart failure and chronic kidney disease. Drugs Context. 2020, 9:2020-7-3. 10.7573\/dic.2020-7-3","journal-title":"Drugs Context"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2017.01.005","article-title":"Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate","volume":"69","author":"Di Lullo L","year":"2017","unstructured":"Di Lullo L, Bellasi A, Barbera V, et. al.. Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate. Indian Heart J. 2017, 69:255-65. 10.1016\/j.ihj.2017.01.005","journal-title":"Indian Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051032","article-title":"Aldosterone and mineralocorticoid receptors-Physiology and pathophysiology","volume":"18","author":"Funder JW","year":"2017","unstructured":"Funder JW. Aldosterone and mineralocorticoid receptors-Physiology and pathophysiology. Int J Mol Sci. 2017, 18:1032. 10.3390\/ijms18051032","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2018.6.01","article-title":"Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries","volume":"69","author":"Sztechman D","year":"2018","unstructured":"Sztechman D, Czarzasta K, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Zera T. Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries. J Physiol Pharmacol. 2018, 69:10.26402\/jpp.2018.6.01","journal-title":"J Physiol Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.099796","article-title":"Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure?","volume":"51","author":"Yu Y","year":"2008","unstructured":"Yu Y, Wei SG, Zhang ZH, Gomez-Sanchez E, Weiss RM, Felder RB. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure?. Hypertension. 2008, 51:727-33. 10.1161\/HYPERTENSIONAHA.107.099796","journal-title":"Hypertension"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2014.08.014","article-title":"Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis","volume":"91","author":"Gomez-Sanchez EP","year":"2014","unstructured":"Gomez-Sanchez EP. Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis. Steroids. 2014, 91:20-31. 10.1016\/j.steroids.2014.08.014","journal-title":"Steroids"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00407.2011","article-title":"Epithelial Na\u207a sodium channels in magnocellular cells of the rat supraoptic and paraventricular nuclei","volume":"302","author":"Teruyama R","year":"2012","unstructured":"Teruyama R, Sakuraba M, Wilson LL, Wandrey NE, Armstrong WE. Epithelial Na\u207a sodium channels in magnocellular cells of the rat supraoptic and paraventricular nuclei. Am J Physiol Endocrinol Metab. 2012, 302:273-85. 10.1152\/ajpendo.00407.2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-14-0471","article-title":"Mineralocorticoid receptors in the heart: Lessons from cell-selective transgenic animals","volume":"224","author":"Young MJ","year":"2015","unstructured":"Young MJ, Rickard AJ. Mineralocorticoid receptors in the heart: Lessons from cell-selective transgenic animals. J Endocrinol. 2015, 224:R1-13. 10.1530\/JOE-14-0471","journal-title":"J Endocrinol"},{"key":"ref23","article-title":"Aldosterone in heart and kidney diseases","volume":"46","author":"Rentoukas EI","year":"2005","unstructured":"Rentoukas EI, Lazaros GA, Zirogiannis PN. Aldosterone in heart and kidney diseases. Hell J Cardiol. 2005, 46:408-19.","journal-title":"Hell J Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland FR","year":"2020","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, et al.. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation. 2020, 142:1236-45. 10.1161\/CIRCULATIONAHA.120.047643","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma A","year":"2022","unstructured":"Verma A, Vaidya A, Subudhi S, Waikar SS. Aldosterone in chronic kidney disease and renal outcomes. Eur Heart J. 2022, 43:3781-91. 10.1093\/eurheartj\/ehac352","journal-title":"Eur Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/336376-neurohumoral-dysregulation-in-acute-myocardial-infarction-with-chronic-kidney-disease-implications-for-prognosis-and-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:13:20Z","timestamp":1759396400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/336376-neurohumoral-dysregulation-in-acute-myocardial-infarction-with-chronic-kidney-disease-implications-for-prognosis-and-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.93692","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}